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ABSTRACT 
BACKGROUND AND RATIONALE 
The Cape Town Metro District Health Service (MDHS) has introduced a Diabetic Retinopa-
thy Screening (DRS) programme incorporating retinal fundal photography in diabetic ser-
vices at primary health care (PHC) facilities. Hitherto, coverage of the DRS programme has 
been less than optimal in part due to volumes of diabetic patients attending PHC facilities. 
The aim of this study was to identify possible sub-groups of patients, attending the Cape 
Town DRS Programme, who are at most risk of diabetic retinopathy and might be priori-
tised for early diabetic retinopathy detection and subsequent sight-saving treatment. 
METHODOLOGY 
A case-control study of risk factors for treatment-requiring diabetic retinopathy was conduct-
ed. This research sampled participants from the DRS programme provided by the MDHS eye 
care team to Type II diabetics attending public PHC facilities within the Klipfontein and 
Mitchells Plain Sub-Districts. Based on fundal images, cases were selected as those requiring 
ophthalmological treatment; and controls (three matched per case by area of residence) as 
those judged as not requiring ophthalmological treatment for diabetic retinopathy. Data on 
possible risk factors (clinical, laboratory) were extracted from the patients’ folders. 
RESULT 
The study included 453 participants, of whom 113 (24.9%) were cases and 340 (75.1%) were 
controls. Three factors were significantly associated with treatment-requiring diabetic 
retinopathy on multivariate analysis: Insulin dependency (OR of 2.96, 95% CI: 1.75 – 5.00); 
duration of diabetes of more than 10 years (OR of 3.44, 95% CI: 2.06 – 5.74) and sustained 
hyperglycaemia over the past six months (OR of 3.73, 95% CI: 1.69 – 8.22). A screening al-
gorithm combining these criteria had a sensitivity of 61.2% (95% CI: 51.9 – 70.5). 
CONCLUSION 
The findings indicate that a sub-set of patients attending the DRS programme in the Klip-
fontein and Mitchells Plain Sub-Districts have a greater likelihood of presenting with 
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treatment-requiring diabetic retinopathy. Further research is required to develop a 
tool that is sufficiently sensitive to safely prioritise patients for fundal screening. 
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CHAPTER ONE: INTRODUCTION 
BACKGROUND 
It is predicted that by 2030 the global diabetic population will more than double from the 171 
million people living with diabetes in 2000 (Bradshaw, Norman, Pieterse and Levitt, 2007). 
Sub-Saharan Africa will not be spared, and it is estimated that the diabetic population will 
increase by 80% from 10.4 million to 18.7 million by 2025 (Sambo, 2007). The prevalence of 
diabetes in South Africa is on the increase due to the cumulative effect of unhealthy lifestyle 
choices such as lack of exercise and poor nutrition. These lifestyle choices are promoted by 
prevailing socio-economic conditions e.g. poverty and urbanisation, and the policies which 
increase the import of low nutritional-value food products (Mash, 2010). 
 Diabetes mellitus, a complex chronic disease, demands extensive public health resources to 
prevent and treat the resultant plethora of complications (Mash, 2010). Diabetes impacts on 
both the macro- and micro-vascular systems leading to irreversible damage to these systems. 
Various studies have identified and described the risk factors associated with the incidence of 
diabetes such as obesity, smoking, and co-morbidities. However, there is little available in-
formation regarding risk factors and the onset and progression of diabetic retinopathy (Mash, 
2010), although the general consensus is that the known risk factors for diabetes are also as-
sociated with the progression of diabetic retinopathy. The Early Treatment of Diabetic 
Retinopathy Study (ETDRS) is an example of a study where the risk factors for proliferative 
diabetic retinopathy were investigated (Davis et al., 1998). It identified elevated glycated 
haemoglobin (HbA1C) as a key risk factor. 
Diabetic Retinopathy, a posterior ocular segment vascular disease which will affect 30% of 
all diabetics, is now the primary reason of blindness in the working age population. The shift 
in blindness attributed to posterior segment ocular disease has coincided with an aging popu-
lation and the rise in non-communicable diseases (Cook and Qureshi, 2005). Diabetic 
retinopathy is largely asymptomatic in its early stage, which necessitates regular effective 
retinal screening. However only a small percentage of diabetics undergo diabetic retinal 
screening on a regular basis (Cook, 2013). 
The increased prevalence of chronic disease in sub-Saharan Africa will necessitate the re-
structuring of primary health care to cater in the most efficient manner for the increased 
burdens, whilst also maintaining patients in good health as long as possible.  
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Chronic non- communicable disease care in South Africa is provided through a network of 
primary healthcare (PHC) facilities, which not only face a growing burden of non-commu-
nicable disease but also of communicable diseases and other health concerns, in what is 
known as a quadruple burden of disease (Mash, De Vries and Abdul, 2007). 
The National Guideline for Prevention of Blindness in South Africa (an adaptation of WHO 
guidelines) offered some indication of policies to champion eye care services in South Africa 
(NDOH, 2002). However, the concurrent HIV/AIDS epidemic as well as other more pressing 
social and health issues has constrained the implementation of this policy. The release of the 
NHI White Paper brief has reaffirmed the importance of available eye care services at public 
primary health care service level, and emphasizes the positive economic impacts of good eye 
care (NDOH, 2015). 
The main purpose of a Diabetic Retinal Screening (DRS) Programme is to prevent sight loss, 
as well as providing information on the overall systemic health of an individual. The advent 
of new technology such as non-mydriatic fundus cameras which allows for greater sensitivi-
ty, quantity and ease of use has made diabetic retinopathy screening viable; and enabled im-
plementation of diabetic guidelines which require annual retinal screening. 
As the prevalence rises, the services to prevent and treat diabetes will become increasingly 
stretched, making it difficult to screen diabetics on an annual basis for diabetic retinopathy. 
The purpose of this study is to provide the primary health care practitioner with an uncom-
plicated algorithm to assess a diabetic patient’s risk of having treatment-requiring diabetic 
retinopathy, so that the patient may be prioritised for fundal photography and subsequently 
specialized treatment if need be. 
RESEARCH SETTING 
The City of Cape Town has an estimated population of 3.7 million of which approximately 
80% is dependent upon the public health system for their health care needs. In Cape Town, 
the Metro District Health Services (MDHS) provide primary care to the uninsured population 
through a network of 45 Community Health Centres (CHC). It is currently estimated that 
28,000 patients have been diagnosed with diabetes, and are receiving chronic care at the vari-
ous primary health care facilities within the MDHS (Mash, Levitt, Steyn, Zwarenstein and 
Rollnick, 2012).  
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The study was conducted of the diabetic population who receive their anti-diabetic treatment 
at one of nine PHC facilities which fall within the geographical boundary of the Klipfontein 
and Mitchells Plain Sub-Districts, which are governed together as a “sub-structure” of the 
Cape Town Metropolitan District. 
The Klipfontein and Mitchells Plain Sub-Districts, form part of what is known as the Cape 
Flatlands; an urban sprawl of majority low cost housing and informal settlements. The Cape 
Flatlands has a population of half a million, which has seen an increase of 27% over the last 
decade. More than two-thirds of the population resides in formal dwellings with the majority 
having access to the basic amenities i.e. sanitation, water and electricity. The sub-districts 
have an unemployment rate of 32%, and a low percentage (37%) of the population over the 
age of 20 have completed schooling (Stats SA, 2013). The Cape Flatlands has become syn-
onymous with poverty, violence and despair. 
PHC services within the Klipfontein and Mitchells Plain Sub-districts are provided through 
four and five day hospitals, respectively. These are predominately nurse driven services, and 
are the first point of service for the majority of people with chronic disease within the area. 
The Mitchells Plain District Hospital serves as a secondary care level referral hospital for the 
PHC facilities. 
The Diabetic Retinal Screening (DRS) Programme hosted at primary health care level 
throughout the Cape Town Metro District Health Services (MDHS) uses a non-mydriatic 
camera (gold standard) to capture fundal images which are then graded, and further man-
agement recommended. This forms the primary point of case identification at public 
health care level of diabetic retinopathy (including secondary ocular pathology) with sub-
sequent referral to tertiary care level for further management. 
PROBLEM STATEMENT 
The integration of eye care services into the comprehensive health care package provided at 
primary public health care level has not been adequately realised. The lack of available eye 
care services has been compounded by an increase in the demand for eye care services for 
diseases such as diabetic retinopathy, glaucoma and cataracts. The ever-increasing aging pop-
ulation as well as an increase in non-communicable disease has put added strain on eye care 
services.  
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As with screening programmes generally (Hofman, Cook and Levitt, 2014), diabetic retinal 
screening is only of value if it is integrated into a holistic care package that ensures adequate 
coverage through screening and with subsequent abnormal results acted upon. Monitoring 
systems often focus on the amount of diabetic retinal screenings conducted, neglecting quality 
and linkage to care aspects. In addition, where large volumes of patients are being screened, 
those most in need may not be identified or prioritised. 
The MDHS is in the process of formulating a comprehensive eye care program, and one of 
the key areas for which evidence is required is how best to improve the detection and man-
agement of diabetic retinopathy (MDHS, 2011). Retinal Camera Imagery (RCI) currently 
provides the method for doing this, but given the large volumes of patients requiring screen-
ing, this study seeks to answer the question whether it is possible to identify patients most 
likely to have treatment-requiring retinopathy on clinical grounds. This should not undermine 
the present guidelines of annual retinal screening for all diabetics, but enhance the efficiency 
and effectiveness of the screening programme. Carmichael, Carp, Welsh and Kalk (2005) 
point out that within a context of resource scarcity, an effective and sustainable DRS protocol 
is of great importance if we are to successfully address avoidable blindness. 
Laser photocoagulation is the primary treatment for diabetic retinopathy in South Africa, and 
the success and prognosis is dependent on the degree of diabetic retinopathy. The best out-
come is produced by the early treatment of proliferative diabetic retinopathy and/or diabetic 
macular oedema, but the concern is that too many patients with diabetic retinopathy present 
at ophthalmology for treatment when the disease is advanced (Cook, 2013). 
Identifying risk factors associated with treatment-requiring diabetic retinopathy may as-
sist with the creation of an at risk diabetic retinopathy patient profile, which would en-
able better case detection. 
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AIM 
The aim of this study was to identify sub-groups of Type II diabetic patients attending the 
Cape Town Diabetic Retinopathy Screening Programme who might benefit the most from, 
and should be prioritised for, early diabetic retinopathy detection and treatment. 
OBJECTIVES 
• To assess Type II diabetic patients who require laser treatment for diabetic retinopathy 
(cases) and those who do not require laser treatment (controls) based on fundal pho-
tography; 
• To compare the risk profile of cases requiring laser treatment based on fundal 
photography to their matched controls; 
• To identify risk factors, if any, associated with treatment requiring diabetic retinopathy; 
• To propose a profile of patients most likely to require treatment, and to test the 
performance of simple algorithms to prioritise patients for fundal photography. 
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CHAPTER TWO: LITERATURE REVIEW 
In this section I outline the international and national burden of diabetes, and the impact it has 
on the health system of a country. Diabetic retinopathy, a complication of diabetes and the 
main focus of this dissertation, will then be discussed and the available evidence on risk fac-
tors reviewed. The section will conclude with the identification of the knowledge gap sur-
rounding diabetic retinopathy and its risk factors, and how this dissertation will attempt to 
address it, with the view to improving Diabetic Retinopathy Screening (DRS) in public pri-
mary health care settings. 
DIABETES MELLITUS 
The American Diabetes Association (1998:2180) defines diabetes as: “…a metabolic disorder 
primarily characterized by elevated blood glucose levels and by microvascular and cardio-
vascular complications that substantially increase the morbidity and mortality associated with 
the disease and reduce the quality of life”. Diabetes is sub-divided into two Types: Type I Di-
abetes, constituting approximately 10% of the cases, who are wholly dependent on exogenous 
insulin due to the absolute lack of insulin production/secretion; and Type II Diabetes, repre-
senting 90% of all cases, characterized by a relative lack of insulin production and insulin 
resistance. Type II diabetes is further sub-classified into Insulin Dependent Diabetes Mellitus 
(IDDM) or Non-Insulin Dependent Diabetes Mellitus (NIDDM) (Innes, 2009). Diabetes is a 
complex disease for which the treatment and management demand significant health re-
sources i.e. human, financial and equipment. The accessibility of these health resources is 
most often unequally distributed along a financial gradient, with poor people having fewer 
resources available to them (Landan & May, 2013). 
GLOBAL DIABETIC BURDEN 
Recent global statistics published by the World Health Organization (2016) indicate that there 
are 422 million people with diabetes worldwide, with a high proportion residing in develop-
ing countries. In 2014, diabetes resulted in 1.5 million deaths worldwide, with an additional 
2.2 million deaths resulting from diabetes related cardiovascular complications. 
Almost half of these deaths occurred prior to the age of seventy years, indicative of the high 
levels of premature deaths attributed to diabetes. 
Africa bears the brunt of the global disease burden, with an increase in non-communicable 
disease over the past decade.  
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The Africa region’s diabetic adult population is estimated at 14.2 million, with South 
Africa accounting for 2.3 million of these. The Africa Region also has the highest number 
of undiagnosed diabetics (International Diabetic Federation, 2015). 
GLOBAL RESPONSE TO DIABETES AND OTHER NCDS 
Chan (WHO, 2016) argues that the rapid increase in the diabetes prevalence in the last two 
decades is a sign of a shift towards increasingly obesogenic lifestyles, which have come as a 
result of a rise in urbanisation and changes in the food environment within developing coun-
tries. Prevention of Type II diabetes requires government action and global partnerships in 
the promotion of healthy food consumption and reduced production and promotion of poor 
quality food products (Mash, 2010). 
The growing burden of diabetes is compounded by the ongoing high communicable disease 
burden. In South Africa, the concomitant ageing HIV-infected population is exacerbating the 
diabetic epidemic. The low availability of health care personnel in such a context makes it 
difficult to address this double burden with any lasting impact (Hofman, 2014). Davies and 
Mullan (2016) also argue that the lack of new research leaves us with little evidence on which 
to base our actions to address the double burden. 
A number of global statements and processes seek to address the increase in diabetes preva-
lence. These include the United Nations General Assembly Outcome Documents on Non-
Communicable Diseases and the Sustainable Development Goals (SDG) adopted in Sep-
tember 2015 (UN, 2015). These documents outline the importance of supportive governance, 
combined with the availability of affordable, accessible and sustainable health care, which 
includes preventative screening, availability of medicines and health promotion. They also 
recognise the intrinsic relationship between development and population health and the need 
for active trans-national participation in addressing diabetes. 
The South African government has also initiated policies to pro-actively curb the incidence of 
diabetes and other NCDs, such as the recent sugar-tax, and smoking and salt regulations. 
These initiatives are imperative if one considers that complications from diabetes, stroke and 
coronary heart disease resulted in a cost of nearly $2 billion dollars in South Africa between 
2005 and 2015 (Hofman, 2014). 
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EYE HEALTH AND DIABETES 
Throughout Africa cataracts remain the leading cause of avoidable blindness, accounting for 
more than half of blindness (Lewallen and Courtright, 2001). In South Africa, cataracts and 
refractive errors are still the leading causes of blindness, and are being addressed through the 
roll out of the first phase of the “Vision 2020” initiative. However, with an ageing population 
diabetes, glaucoma and age-related macular degeneration (ARMD) are slowly gaining ground 
in the causes of blindness (Read and Cook, 2007). A recent study conducted in Cape Town 
which formed part of the Rapid Assessment of Avoidable Blindness (RAAB) programme, re-
flected a prevalence of blindness comparable to similar studies in other regions. Noticeably, a 
significantly higher proportion of those patients with severe visual loss had posterior segment 
disease. This indicates a gradual shift of avoidable visual loss away from cataracts towards 
posterior segment diseases (Cockburn et al., 2012). 
Diabetic retinopathy is the leading cause of blindness in the adult population between 30 and 
65 years of age in developed countries (Mollentze, 2003). This might be attributed to the 
greater access to services for other causes of blindness such as cataracts. In South Africa, di-
abetic retinopathy is the third leading cause of blindness with a reported prevalence of 20% 
amongst the diabetic population (Cook and Read, 2007). 
Diabetic retinopathy is a micro-vascular disorder resulting in damage to the retinal vascular 
structure and is the primary ophthalmic condition associated with diabetes. It is associated 
with a multitude of other ocular conditions: cataract, glaucoma, and presbyopia, exacerbating 
the effects of retinopathy (IDF, 2015). 
The high prevalence of diabetic retinopathy emphasizes the importance of routine retinal ex-
amination of diabetics at follow-up. This is seemingly a simple task, but the reality is that a 
low number of diabetics undergo regular annual retinal examination, due to lack of the neces-
sary equipment combined with the lack of skills of the health personnel in performing some 
form of fundal examination e.g. ophthalmoscopy, retinal imagery or slit-lamp evaluation 
(Mollentze, 2003). Furthermore, the initial asymptomatic stage of diabetic retinopathy lulls 
the patient into a false sense of security exacerbated by their lack of knowledge pertaining to 
diabetic eye care. A study in Finland found that twenty percent of diabetics were not aware of 
the ocular complications associated with diabetes, and for those that knew that diabetes led to 
visual disturbance, the majority were not informed on how to prevent this (IDF, 2015). 
 
 
 
 
 9
Vision 2020, an initiative launched by the WHO in partnership with various custodians of eye 
care services globally, advocates the right to sight, and aims to eliminate avoidable blindness 
by the year 2020. Guidelines in accordance with Vision 2020 have been drafted by the South 
African National Department of Health, outlining various ocular disorders and strategies to 
address them (NDOH, 2002). However, the document does not provide guidance on translat-
ing these strategies into workable solutions at a primary care level. 
SCREENING AND TREATMENT OF DIABETIC RETINOPATHY 
Diabetic-related blindness can be prevented through implementing efficient retinal screening 
programmes and initiating early treatment procedures (Stefànsson et al., 2000). Screening 
for, and treating diabetic retinopathy is considered to be the most cost-effective medical pro-
cedure known today (Hofman, Cook & Levitt, 2014). Cook (2013) has argued that retinal 
screening provides us with a state of the micro-vascular system which may provide insight 
into other co-morbidities, therefore making diabetic retinopathy screening (DRS) a vital pub-
lic health investment. In countries where diabetic retinal screening has become part of rou-
tine public health care a drop in diabetic-related blindness has been achieved (Cook, 2014). 
However, even in developed countries with a comprehensive DRS programme, adherence to 
the guidelines of annual fundal photography of diabetics is still a challenge, with annual 
screening levels ranging from 34 to 65% of patients in various settings (Ciulla, Amador and 
Zinman, 2003). 
Laser photocoagulation is the primary ophthalmic treatment for diabetic retinopathy. The suc-
cess and prognosis is dependent on the degree of diabetic retinopathy. The best outcome is 
produced by the early treatment of proliferative diabetic retinopathy and/or diabetic macular 
oedema. However, the concern is that too many patients with diabetic retinopathy reach oph-
thalmological services for treatment when the disease is advanced (Cook, 2013). 
Early intervention necessitates regular fundal examination of a diabetic by competent health 
personnel, preferably with the use of a non-mydriatic fundus camera which can clearly cap-
ture all four quadrants of the fundus, and creates a record for future comparison. Images are 
graded by degree of diabetic retinopathy and specifying the absence/presence of macular 
oedema, of which both guide the laser photocoagulation process (IDF, 2015). 
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The Early Treatment of Diabetic Retinopathy Study (ETDRS) developed the rules for treating 
non-proliferative diabetic retinopathy, known as 4-2-1 (IDF, 2015). Treatment is recommend-
ed when: 
- micro-aneurysms are present in all four quadrants, 
- venous beading is present in at least two quadrants 
- intra-retinal microvascular anomalies are present. 
The ETDRS has also indicated that these rules are not hard and fast and can be modified 
based on individual clinical assessments of risk and predictability of rate of progression of 
retinal changes. 
Hofman et al. (2014) suggest that task-shifting may be appropriate for laser treatment, 
whereby an appropriately trained medical officer at secondary level will perform laser photo- 
coagulation to reduce the burden of over-referral at tertiary care level raised as a possible 
stumbling block with the initiation of wide-spread diabetic retinal screening (Cook, 2013). 
Furthermore, this will allow better coordination between secondary and primary level 
diabetic eye care e.g. better communication, referral and sustained follow up. 
RISK FACTORS FOR DIABETIC RETINOPATHY 
Multiple studies have identified and described the risk factors associated with the incidence 
of diabetes (Mash, 2010). Fewer studies have specifically investigated the factors associated 
with the onset and progression of diabetic retinopathy. 
The Early Treatment Diabetic Retinopathy Study (ETDRS) conducted in the United States of 
America is considered the most significant study of diabetic retinopathy to date. It identified 
the following factors for high-risk proliferative diabetic retinopathy: age, type and duration of 
diabetes, HbA1c levels and history of diabetic neuropathy (Davis et al., 1998). 
The Hoorn study conducted in the Netherlands found chronic hyperglycaemia, hypertension 
and abdominal obesity to be significantly associated with incident diabetic retinopathy. In 
contrast, age, sex, Body Mass Index (BMI) and smoking were not significantly associated 
with incident diabetic retinopathy. Studies of the association between diabetic retinopathy 
and BMI, an indication of obesity, which in-turn is associated with insulin resistance, have 
not delivered any conclusive results. However, waist-hip ratio, an indicator of central obesity, 
has been identified as a risk factor for diabetic retinopathy in the EURODIAB Prospective 
Complications Study (Van Leiden et al., 2003). 
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Metabolic abnormalities associated with diabetes such as hyperglycaemia, hypertension and 
dyslipidaemia have been found to be risk factors for the development and progression of dia-
betic retinopathy (Ciulla et al., 2003). HIV infection has been shown to increase the chances 
of developing diabetes (Mash, De Vries and Abdul, 2007), although the relationship with di-
abetic retinopathy has not been investigated. The Wisconsin Epidemiological Study of Dia-
betic Retinopathy (WESDR) indicated that the prevalence of diabetic retinopathy is signifi-
cantly greater in Type II diabetics on insulin therapy compared to Type II diabetics not on 
insulin therapy (Mollentze, 2003). Aspelund et al. (2011) found that type, duration of dia-
betes, HbA1c, systolic blood pressure, sex and the degree of diabetic retinal change were as-
sociated with progression of diabetic retinopathy. Table 1 below summarises the global evi-
dence on the risk factors for diabetic retinopathy 
Table 1: Diabetic retinopathy risk factors identified by various studies 
Risk Factors ET-
DRS
Davis 
et al
Van 
Leiden 
et al.
Aspelund 
et al.
Mol-
lentze
Mehl
sen 
et al.
Ciulla 
et al.
Age x
Gender x x
Decreased 
Visual Acuity
x
Insulin depen-
dant
x x x
Duration of 
diabetes
x x x x
Abdominal 
obesity
x
Hyperglycaemia x x x
HBA1c x x x x
Hypertension x x x x
Dyslipidaemia x
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The risk factors which have been associated with the onset and duration of diabetic 
retinopathy in previous studies have not been quantified and the pathophysiology and 
pathways by which these risk factors impact retinal changes in diabetics are still being 
debated (Ciulla et al., 2003). 
Aspelund et al. (2011) assessed risk factors for progression of diabetic retinopathy in order to 
safely customise the DRS interval, and found that a mathematical algorithm utilizing the data 
of these known risk factors: HbA1c, waist-hip ratio and hypertension, allows one to safely 
customize individual DRS intervals. The use of customised DRS intervals reduced the annual 
number of diabetics to be screened by 40% (Looker et al., 2013). Similarly, Mehlsen, Erland-
sen, Poulsen and Bek (2011) in their research to individually customize the DRS interval, in-
vestigated the following risk factors: diabetes type, onset and duration of diabetes, gender, 
HbA1c, blood pressure and severity of diabetic retinopathy. Of these, the degree of diabetic 
retinopathy, HbA1c and the patient’s age at diagnosis were associated with the progression of 
diabetic retinopathy. On the basis of these findings, more effective and efficient approaches to 
the delivery of the DRS were developed. These studies highlight the value of investigating 
risk factors associated with treatment requiring diabetic retinopathy not only as a pre-screen-
ing tool but also as a predictor of diabetic retinopathy progression. 
BARRIERS TO DIABETIC EYE CARE 
Current guidelines dictate that all diabetics require regular comprehensive ocular examina-
tions, which may be conducted by a well-trained cadre of health personnel including: com-
munity health workers, optical dispensers, retinal camera technicians, primary health care 
nurses, optometrists, medical officers and ophthalmologist (NDOH, 2002). This is achievable 
if the health system structures are in place which encompass the necessary equipment, quali-
fied health personnel, appropriate referral pathways and patient education. Cook (2013) di-
vides DRS programmes into either structured or opportunistic, where structured involves a 
clearly defined systematic approach detailing the various referral pathways and opportunistic 
alluding to the availability of fundal imagery but without the emphasizes on collaboration 
between the various stakeholders. The current DRS programme in the MDHS can be regard-
ed as a combination of both, where DRS is available at primary health care level but with 
poor attendance and inadequate identification of high risk profile patients. 
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Apart from the MDHS programme, the only other DRS programme described on the African 
continent from which to draw insights is the Kilimanjaro Diabetic Programme (KDP) in 
northern Tanzania. This project mimics the modus operandi of the MDHS DRS programme, 
whereby retinal screening teams go to public health facilities to capture the fundal images 
with a mobile camera. The KDP reported a low attendance rate in those diabetics who were 
referred for ophthalmic treatment, which highlights the need for future studies to clearly 
identify referral pathways (Cleland et al., 2016). 
In Finland, the Diabetic Retinopathy Barometer project found that even in this developed 
country setting, there is poor integration of eye care services with diabetic case management, 
with illogical investment in tertiary health care focussing on treatment rather than prevention 
and early detection at lower levels of the system. 
KNOWLEDGE GAP 
Risk factors associated with treatment-requiring diabetic retinopathy in the specific context of 
the public health sector in South Africa are not well established. While Aspelund et al. (2011) 
showed that in Denmark it was possible to extend the DRS interval in certain cases with the 
use of the extrapolated individual risk factors, at present there are no such pre-screening tools 
for the South African public sector context which make use of available clinical information. 
An accurate pre-screening algorithm will enable the selection of cases that would benefit the 
most from laser photocoagulation treatment. 
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CHAPTER THREE: METHODOLOGY 
STUDY DESIGN 
A case-control study was conducted to establish the difference in levels of exposure to pos-
sible risk factors for treatment requiring diabetic retinopathy, where cases were those judged 
as requiring laser treatment and controls as those not requiring laser treatment, based on 
fundal photography. 
STUDY POPULATION 
The study population was all diagnosed Type II diabetics receiving their treatment from a 
public primary health care facility situated within the Klipfontein and Mitchells Plain Sub- 
Districts of the Metro District Health Services (MDHS), and meeting the following inclusion 
and exclusion criteria. 
Inclusion criteria: 
Diagnosed Type II diabetics using anti-diabetic medication; resident within the Klipfontein 
and Mitchells Plain Sub-Districts of the Cape Town Metropolitan District; had undergone 
fundal photography screening in the study period. 
Exclusion criteria: 
Type I diabetics; Type II diabetics in which the fundal photographs were un-gradable; Type 
II diabetics receiving their medication at a tertiary health care institution; Type II diabetics 
who have already had laser photocoagulation performed on one of their eyes. 
DEFINITION OF CASES AND CONTROLS 
Cases constituted Type II diabetics who attended the Diabetic Retinopathy Screening (DRS) 
programme and presented with retinopathy requiring treatment based on the Scottish Grading 
Scale of their fundal images; provided that they met the inclusion criteria. Controls were the 
consecutive attendees of the DRS programme (i.e. after the cases) in the same facility who 
presented with normal retinal appearance or mild changes not requiring treatment based on 
the Scottish Grading Scale. 
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SAMPLE SIZE 
Using the statistical calculator on Epi Info 7, the following information was entered: case to 
control ratio of 1:3; risk factor prevalence in the controls of 50%; confidence interval of 95%; 
statistical power of 80% and an estimated odds ratio of 2. This amounted to a study sample 
size of at least 398 participants constituting 100 cases and 298 controls. 
SELECTION AND MATCHING OF CASES AND CONTROLS 
Cases and controls were selected from the diabetic patients participating in the DRS pro-
gramme from February to November 2015. In this period, 3 378 diabetic patients in nine 
clinics of the Klipfontein and Mitchells Plain Sub-Districts were screened. Of these, 381 
(11%) were identified on fundal photography as having an ocular disorder requiring further 
treatment, including, but not limited to diabetic retinopathy. Of these, 185 satisfied the inclu-
sion and exclusion criteria and case definition. The cases were individually matched with 
controls by area of residence in a ratio of 1:3. This allowed for the control of both health ser-
vice accessibility and socio-economic status of the participant. These variables have been 
associated with the prevalence of visual loss found in different communities in Cape Town 
(Cockburn et al., 2012). 
DATA COLLECTION AND COLLATION 
Fundal Photography 
The retina of diabetic patients was photographed with the use of a mobile fundal camera 
(Canon CRII non-mydriatic fundus camera) operated by a retinal camera technician with an 
ophthalmic dispensing diploma. An assistant recorded patient information on a standardised 
sheet. The fundal images concentrated on the central and para-central retina, thus allowing 
for the view of the macula and optic nerve head on a single image; for most images the far 
circumferential retinal periphery was not captured. The majority of patients had two images 
taken- one image per eye. The patients who presented with media opacities e.g. cataracts, 
corneal defects, were dilated with the use of 10mg Tropicamide (Mydriacyl) to allow for a 
better image quality. 
The researcher, an employee of the eye care service provider for the particular sub-district 
throughout the study period, was tasked with the grading of all the fundal images. The 
grader was blind to the information pertained in the patients’ folders at the time of the 
grading.  
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Patient record cards (collated in an alphabetic order) and a flash disk were handed to the 
retinal grader on a daily basis, who assessed each image, recorded findings and made rec-
ommendations. 
The Scottish Grading Scale was used to grade the diabetic retinal changes. This is appropriate 
for grading fundal photographs of the posterior pole and defines the degree of diabetic 
retinopathy in a hierarchical manner including the appearance of the macula (Cook, 2013). 
The standard grading procedure included categorising the images into four categories: 
• No Diabetic Retinopathy detected – annual examination recommended 
• Mild to Moderate Diabetic Retinopathy with no maculopathy – 3/6 months’ follow-up 
fundal imagery recommended 
• Severe Non-Proliferative Diabetic Retinopathy – referral to ophthalmology 
• Proliferative Diabetic Retinopathy – referral to ophthalmology 
The first two categories constituted controls and the second two categories cases. 
Record Review 
The data obtained from each batch of images graded per CHC was collated daily in a spread-
sheet, and a copy of these clinical records stored at the service provider’s base located at 
Woodstock Hospital. In December 2015, the researcher assembled all the cases meeting the 
case definition over the study period and selected three to four controls from the patients 
seen immediately after the case on the same day. Subsequently, all potential study partici-
pants were contacted telephonically to inform them that they had been selected and request-
ing consent to review their clinical folder in the facility. The clinical records were reviewed 
between January and March 2016 by the researcher at each participating facility. A data ex-
traction form was designed (Appendix C) and attached to the back of the eye health record 
card. The data of the variables being investigated were entered and organised in a spread 
sheet along with the other relevant clinical information. 
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Table 2 below lists the data collected/variables studied and their definition 
Table 2: Data/variables and definitions 
Variable Measurement
Age The date of birth was used as reference, and the patient’s age in the year 
2015 was recorded.
Sex The patient’s gender depicted on their clinical sticker was recorded.
BMI This variable is a product of two separate variables: weight (kg)/ height 
(m)2.The height of the patient in meters rounded to the second decimal was 
obtained in the clinical folder and recorded by a clinical nurse using a wall 
length tape. The most recent weight in kilograms rounded to the first dec-
imal was obtained from the most recent scale measurements conducted by 
the clinical staff and recorded in the folder. Subsequently, weight 
(kg)height with each participant’s data were calculated to obtain the BMI 
figure rounded to one decimal point.
Co- morbidi-
ties
The co-morbidities were recorded based upon the diagnosis and medicine 
recorded on the participants’ recent chronic dispensing chart, as signed off 
by the attending medical officer. This categorical data was recorded in ex-
cel spreadsheet.
Insulin de-
pendency
This was recorded as the absence or presence of insulin-therapy on the 
patient’s latest chronic dispensing chart.
Duration of 
diabetes
The duration of diabetes was taken as the time from the start of anti- diabet-
ic treatment. The duration of diabetes was ascertained by direct questioning 
of the patient on the day of the fundal photography by the Retinal Camera 
Imagery (RCI) team, and then verified by reviewing the folder of the partic-
ipants at their respective clinics during the data collection phase of the 
study. Due to the inconsistent nature of record keeping compounded by the 
problem of recall by the patient on the day of the fundal imagery, duration 
was recoded into 5 year intervals.
Smoking 
Status
The smoking of tobacco products as recorded in the clinical folder was 
recorded as a binary (yes/no) variable.
Glycated 
haemoglobin 
levels
This was recorded as percentages up to one decimal point. This reading 
was taken from the last clinical laboratory results filed within the patients’ 
folder provided that it was done within the last two years.
Blood-plasma 
glucose levels
This data was taken as the average of the three most recent measurements 
for each participant with the time-span of these findings ranging at most 
from six months to at least a week. This was recorded up to the first deci-
mal.
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RELIABILITY AND VALIDITY 
The reliability and validity of the study was enhanced through: 
• Recording data using standardised measurement equipment i.e. measuring tape/weight 
scale was similar in make or to assign one piece of equipment per data item being 
measured. 
• Adopting the gold standard for retinal imagery. 
• The retinal camera technician was blinded to the participants of the study as images 
were collected prior to selection of cases. 
• A single retinal grader viewed the fundal images. 
• Verification of the data through reviewing the study participants’ folders to lessen 
recall bias on e.g. treatment received and comorbidities. 
GENERALISABILITY 
The Klipfontein and Mitchells Plain Sub-Districts are two of the eight Sub-Districts which 
form part of the Cape Town MDHS, and the findings are generalizable to these Sub-Districts. 
However, the study participants are likely to exhibit similar characteristics to diabetic patients 
attending the Primary Health Care (PHC) facilities in the other Sub-Districts and are likely to 
be applicable to Type II diabetics receiving care at the different PHC facilities within the 
MDHS. 
DATA ANALYSIS 
Data were entered and organized in an excel spreadsheet and checked for errors and missing 
data. Analysis was done with the help of a statistician using the NCSS 9 Statistical Software, 
which incorporates regression modelling. 
The description of the categorical data i.e. sex, duration, type, co-morbidities and smoking 
was done through frequency distribution and the differences between cases and controls 
assessed using the Pearson’s Chi Square test. 
The normality of distribution of the continuous data was assessed with the use of the 
D’Agostino Skewness test. The data indicating a rejection of normality was then transformed 
into logarithmic values. The description of the continuous data i.e. age, BMI, blood glucose 
level and HbA1c was done through the calculation of the mean, range and 95% confidence 
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intervals. Linear regression was then performed to assess the differences between cases and 
controls. 
Those variables/risk factors that were significantly associated at the 5% level with the 
presence of treatment requiring retinopathy (cases) were entered into a multiple regression 
model and multivariate analysis conducted. 
SENSITIVITY AND SPECIFICITY 
Variables which remained significantly different between cases and controls following mul-
tivariate analysis were combined in various permutations as algorithms for identifying those 
who should be prioritised for the DRS programme. The algorithm was then tested for sensi-
tivity (the ability to identify those with disease), specificity (the ability to exclude those 
without disease), and positive and negative predictive values (the proportions with and 
without the disease). 
ETHICS 
The Senate Research Committee of the University of the Western Cape approved the 
methodology and ethics of this research project in June of 2015 (Appendix B). Subsequently, 
I applied for ethical clearance from the Western Cape Provincial Department of Health to 
allow me to access the participants’ folder at the relevant facilities, and also obtained the 
consent of facility managers. 
The delay in approval from the relevant clinics resulted in my altering the data collection 
from achieving the collection of data on the same day as the fundal imagery. Eventually, 
permission was obtained to access the facilities in December 2015, which meant that I had to 
obtain my consent telephonically and retrospectively obtain the data. 
The selected participants in the study were contacted telephonically in December 2015 and 
informed about the study and what their involvement would entail (Appendix A). Once the 
patient gave verbal consent this was recorded on the eye health record card which contained 
the participant’s contact details and to which the data collection form was attached. The par-
ticipants were reassured that the information obtained from their folder would be kept private 
and confidential. In the analysis all identifiers were removed and data reported in aggregated 
form.  
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The routine standard of care (referral for treatment) was strictly adhered to in patients with 
retinal abnormalities requiring treatment. 
The results of this study once finalised will be fed back to the clinical programme managers 
who will take responsibility to disseminate the information to all parties involved. 
LIMITATIONS 
The retrospective nature of the data collection which entailed folder review did result in a 
greater level of inaccurate or missing data. This was recorded in Excel spreadsheet as miss-
ing. Information relating to the duration of diabetes was difficult to verify and could only be 
recorded as less or more than a specific year. Active clinical folders have records pertaining 
to the last twenty years (presumably then placed in storage due to the bulkiness) which im-
pedes the accuracy of information on the onset of diabetes of those receiving diabetic treat-
ment for more than twenty years. 
The blood glucose level values were susceptible to fluctuation due to absence of conformity 
with regard to time of day and history of food consumption prior to the test. A more accurate 
measurement of the patients’ glycaemic level is the HbA1c level. However, due to lack of 
consistent HbA1c testing of diabetic patients amongst and within clinics a high amount of 
data was missing. This is possibly due to the complex process involved. The majority of dia-
betics had had HbA1c analysis before, however a substantial number has not had one in the 
last year when the data was collected, therefore the variable for the participant was recorded 
as missing. 
Although weight was routinely measured at the clinic, height was somewhat neglected, most 
likely due to emphasis being placed on monitoring the fluctuation of an individuals’ weight in 
contrast to the consistency of an individuals’ height. Participants who are wheelchair-bound 
rarely had their height and weight measured. This made it difficult to assess BMI.  
Visual Acuity (VA) were collected as part of the routine DRS programme, but not analysed as 
the study took into consideration routinely measurable systemic markers performed by prima-
ry health care workers. In certain instances, participants had duplicate folders at their clinic 
which led to gaps in a patients’ clinical history impacting on data collection. 
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CHAPTER FOUR: RESULTS 
The results section first analyses the distribution of cases and controls by facility, age and 
sex. It then compares their clinical and risk factor profiles and distribution of co-morbidities. 
Significant differences between cases and controls are then analysed in a multivariate model. 
Finally, clinical variables showing significant differences between cases and controls are 
tested in different combinations to assess their performance as a pre-screening tool for priori-
tising patients for fundal photography. 
DISTRIBUTION OF STUDY SAMPLE 
During the study period, 3378 diabetics underwent retinal camera imagery, of whom 381 
(11.3%) presented with ocular pathology e.g. cataracts and diabetic retinopathy, which re-
quired further investigation and intervention by an ophthalmologist. Of these, 185 satisfied 
the inclusion criteria as cases i.e. diabetic retinopathy requiring treatment. A total of 113 con-
sented to participate in the study, giving a response rate of 61.1%. Of the 439 controls who 
were contacted, 340 (77.5%) consented to participate. 
Table 3 gives the distribution of the study sample by facility. The number of diabetics at-
tending the Diabetic Retinopathy Screening (DRS) in the study period differed by clinic, 
depending not only upon the total number of diabetics receiving their health care at the par-
ticular clinic, but also on the availability of space and resources to host the fundal imagery. 
Mitchells Plain CHC contributed one-fifth of the diabetics screened, while Nyanga CHC, 
where the DRS programme only started in June of 2015, had the lowest number of screen-
ings conducted. 
During case selection three to four controls (depending on availability) were selected from 
the same screening batch matched for area of residence. As Table 3 indicates, the distribution 
of the study sample more or less reflects the distribution of the screening programme in the 
clinics. The lowest proportion of participants garnered from the screened population was at 
Cross Roads CHC, which was in part due to poor rate of retrieval of the folders upon review. 
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Table 3: Distribution of diabetics screened (n = 3 378), cases (n=113) and controls (n=340) 
by clinic 
AGE-SEX PROFILE OF CASES AND CONTROLS 
The majority of study participants were 50 years or older (Table 4). There were few partici-
pants under the age of 30 years, as Type I diabetics who present at a younger age were ex-
cluded from the study population. There was a statistically significant difference in mean age 
between the cases (58.2 years) and controls (55.6 years) (p-value = 0.043). 
There were three times more female participants than male participants in the overall sample, 
but there were no differences in the sex distribution between cases and controls. 
Name of clinic Diabetics screened 
(% total)
Cases 
(% total)
Controls 
(% total)
Total sample 
(% total)
Cross Roads (CRC) 228 (6.8) 3 (2.7) 4 (1.2) 7 (1.6)
Dr Abdurahman (DAC) 506 (15.0) 14 (12.4) 62 (18.2) 76 (16.8)
Gugulethu (GDH) 305 (9.0) 17 (15.0) 41 (12.0) 58 (12.8)
Hanover Park (HPH) 437 (13.0) 9 (8.0) 25 (7.4) 34 (7.5)
Heideveld (HVP) 507 (15.0) 9 (8.0) 43 (12.7) 52 (6.6)
Inzame Zabantu (IZC) 326 (9.7) 9 (8.0) 21 (6.2) 30 (6.6)
Mitchells Plain (MHC) 690 (20.4) 28 (24.8) 90 (26.5) 118 (26.1)
Nyanga (NGC) 69 (2.0) 7 (6.2) 12 (3.5) 19 (4.2)
Tafelsig (TAF) 310 (9.2) 17 (15.0) 42 (12.4) 59 (13.0)
Total 3 378 (100) 113 (100) 340 (100) 453 (100)
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Table 4:  Age-sex profile of total sample ( n = 453), cases ( n = 113) and controls ( n = 340) 
*Confidence Interval 
Variable Cases (% 
total)
Controls 
(% total)
P -Value
Age Distribution 20-29 0 (0.0) 3 (0.9%)
30-39 1 (0.9) 14 (4.1)
40-49 17 (15.1) 44 (12.9)
50-59 36 (31.9) 133 (39.1)
60-69 48 (42.5) 104 (30.6)
70-80 11 (9.7) 40 (11.8)
>80 0 (0.0) 2 (0.6)
Total 113 (100) 340 (100)
Mean Age (Years) 58.2 55.6 0.043
95% CI*(%) 56.5 – 59.9 54.6 – 56.6
Range 38 – 80 23 – 82
Sex Female 88 (77.9) 261 (76.8) 0.808
95% CI (%) 69.2 - 86.6 71.7 - 81.9
Male 25 (22.1) 79 (23.2)
95% CI (%) 5.8 - 38.4 13.9 - 32.5
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The difference in age distribution between cases and controls is further illustrated in Figure 1, 
indicating the skewed distribution towards older age groups of the cases. 
Figure 1: Age distribution of cases (n=113) and controls (n=340) 
There were also statistically significant differences in mean ages between clinics (p = 0.001). 
Two clinics - Cross Roads (CRC) and Inzame Zabantu (IZC) - had younger patient popula-
tions (for both cases and controls). In a further two clinics - Mitchells Plain (MHC) and 
Hanover Park (HPH) - the mean age of the controls was slightly higher than the cases (Fig-
ure 2). 
 
Figure 2: Mean age of cases and controls per clinic 
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CLINICAL PROFILE OF CASES AND CONTROLS 
The clinical profile of cases and controls, with respect to the duration of diabetes, the depen-
dency on insulin, and blood glucose and HbA1c levels is shown in Table 5. 
Duration of diabetes (Table 5) was categorised into less than five years, between five and ten years 
and more than ten years. There was a significant difference in the proportion of cases and controls 
who had been on anti-diabetic treatment for ten years or more. Cases were twice as likely to have 
been on treatment for ten years or more (Pearson’s Chi-Square, p < 0.001). 
The usage of insulin was recorded as a binary variable (Yes/No) without taking into consideration 
the duration that the patient may have been on insulin therapy, nor the type of insulin and dosage 
currently being used by the patient. There was also a marked and significant difference between 
cases and controls in the usage of insulin (Pearson’s Chi- Square, p < 0.001). 
Table 5: Clinical profile of sample (n = 453) cases (n = 113) and controls (n=340) 
Variable Category Cases (% 
total)
Controls (% 
total)
P Value
Duration 
of Dia-
betes 
(years)
Missing 10 (9.7) 34 (10.0)
< 0.001
95% CI (%) 0.0 - 27.2 0.0 - 20.1
0 – 4.99 13 (12.6) 107 (35.0)
95% CI (%) 0.0 - 29.8 26.4 - 43.6
5 – 9.99 24 (23.3) 110 (36.0)
95% CI (%) 7.1 - 39.5 27.5 - 44.5
10+ 66 (64.1) 89 (29.1)
95% CI (%) 53.0 - 75.2 20.1 - 38.1
Total 113 (100) 340 (100)
Insulin 
Depen-
dency
Yes 79 (69.9) 111 (32.7)
95% CI (%) 59.8 - 80 24.0 - 41.4
No 34 (30.1) 229 (67.4)
95% CI (%) 14.7 - 45.5 61.3 - 73.5
Total 113 (100%) 340 (100%) < 0.001
Blood 
Glu-
cose 
Level 
(mmol/
L)
Mean 12.5 10.6
95% CI 11.7 – 13.3 10.2 – 11.0
Range 5 – 24.5 4 – 20.5
Logarithmic Mean 2.5 2.3 0.023
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The distribution of mean blood glucose levels of the total sample is indicated in Figure 3. Due to signifi-
cant outliers and skewness in the distribution of data, neither the cases nor the controls passed the normal-
ity test (D’Agostino Skewness) for distribution of blood glucose levels. Logarithmic values were thus 
computed producing a better distribution (Figure 4) and a more valid use of tests of statistical signifi-
cance. Linear regression of the mean logarithmic value of blood glucose for cases and controls indicated 
a statistically significant difference between cases and controls (p=0.023). 
    
Figure 3: Distribution of the sample’s mean blood glucose levels (cases and controls combined) 
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Figure 4: Distribution of the sample’s blood glucose levels after logarithmic transformation 
Data were available on HbA1c levels for 88 out of the 113 cases (77.9%) and 285 out of the 
340 controls (83.8%). The distribution of the HbA1c data similarly did not pass the 
D’Agostino Skewness test, and the HbA1c data was also transformed into logarithmic values 
before tests of association applied. Statistically significant differences in the mean logarith-
mic values of the HbA1c data were also found amongst the cases and controls (p-value = 
0.014). 
RISK FACTORS IN CASES AND CONTROLS 
There was no statistically significant difference (P=0.698) in current smoking status between 
cases (31.4%) and controls (29.4%) (Table 6). 
Data on BMI was available for 96.5% and 95.3% of cases and control respectively. The mean 
BMIs for both cases (30.9) and controls (32.7) were in the obese range, and differences were 
not statistically different (p=0.163). 
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Table 6 : Risk factors of sample ( n = 453) cases ( n = 113) and controls ( n = 340) 
CO-MORBIDITIES IN CASES AND CONTROLS 
Co-morbidities were highly prevalent in the study population, with only 1 case and 19 controls not receiv-
ing treatment for a condition other than diabetes (Table 7). There were 224 instances of co-morbidity 
(mean 1.98 per person) for cases and 669 (mean 1.97 per person) for controls. A very high percentage of 
both cases (96.5%) and controls (86.8%) received anti-hypertensive treatment. Furthermore, treatment for 
cholesterol and osteoarthritis was also common for both cases and controls. Linear regression indicated a 
statistical significant difference in hypertension treatment between cases and controls (p= 0.004).  
Variable Category Cases (% 
total)
Controls 
(% total)
P-Value
Smoking Status Missing 8 (7.6) 24 (7.1)
95 % CI (%) 0.0 - 25.3 0.0 - 17.3
Not Smoking 72 (68.6) 223 (70.6)
95 % CI (%) 58.3 - 78.9 64.8 - 76.4
Smoking 33 (31.4) 93 (29.4)
95 % CI (%) 16.1 - 46.7 20.5 - 38.3 0.698
Total 113 (100) 340 (100)
Body Mass 
Index
Mean 30.9 32.7
95% 
CI
29.5 – 32.3 31.9 – 33.5
Range 18.2 – 54.1 16.7 – 57.0
Logarithmic 
Mean
3.4 3.5 0.163
95% 
CI
3.4 – 3.4 3.5 – 3.5
Range 2.9-4.0 2.8-4.0
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Table 7: Treatment for co-morbidities in cases (n=113) and controls (n=340) 
Co-morbidity Total Case Control P-Value
Hypertension 404 (89.2%) 109 (96.5%) 295 (86.8%) P=0.004
95% CI 86.2% - 92.2% 93.0% - 100% 82.9% - 90.7%
Osteoarthritis 184 (40.6%) 36 (31.9%) 148 (43.5%) P=0.029
95% CI 33.5% - 47.7% 16.7% - 47.1% 35.5% - 51.5%
Cholesterol 102 (22.5%) 32 (28.3%) 70 (20.6%) P=0.08
95% CI 14.4% - 30.6% 12.7% - 43.9% 11.1% - 30.1%
Ischemic Heart Dis-
ease
49 (10.8%) 17 (15.0%) 32 (9.4%)
Chronic Obstructive 
Pulmonary Disease
33 (7.3%) 9 (8.0%) 24 (7.1%)
Gastro- oesophageal 
reflux disease
33 (7.3%) 4 (3.5%) 29 (8.5%)
None 20 (4.4%) 1 (0.9%) 19 (5.6%)
Asthma 14 (3.1%) 2 (1.8%) 12 (3.5%)
Congestive Car-
diac Failure
13 (2.9%) 5 (4.4%) 8 (2.4%)
Hypothyroidism 7 (1.5%) 1 (0.9%) 6 (1.8%)
Benign Prostate 
Hypertrophy
6 (1.3%) 3 (2.7%) 3 (0.9%)
Epilepsy 6 (1.3%) 1 (0.9%) 5 (1.5%)
Gout 6 (1.3%) 0 (0%) 6 (1.8%)
Depression 6 (1.3%) 3 (2.7%) 3 (0.9%)
Rheumatoid 
Arthritis
5 (1.1%) 1 (0.9%) 4 (1.2%)
HIV/Aids 5 (1.1%) 0 (0%) 5 (1.5%)
 
 
 
 
MULTIVARIATE ANALYSIS AND SCREENING MODELS 
Significant differences between cases and controls on bivariate analysis were entered into a 
multivariate logistic regression model (Table 8). These included factors which remained sig-
nificantly associated with diabetic retinopathy in the multiple regression model: duration of 
diabetes of more than ten years, insulin dependency and the log value of blood glucose level. 
Blood glucose levels were chosen rather than HbA1c for inclusion in the model, due to the 
large amount of missing HbA1C data.  
Linear regression indicated statistically significant differences in treatment for hypertension 
(p=0.004) and osteoarthritis (p=0.029) between cases and controls. However, when combined 
with other factors on multivariate analysis these factors were no longer associated with 
treatment-requiring diabetic retinopathy and were excluded from the development of the 
screening algorithm.  
Table 8: Factors associated with treatment requiring retinopathy: multi-variate analysis 
(controls =0, cases=1) 
The three risk factors for treatment-requiring diabetic retinopathy - duration of diabetes 
treatment, insulin dependency and blood glucose level - were combined in various permu-
tations and assessed as a screening algorithm to identify at risk patients who could poten-
tially be fast- tracked for fundal imagery. 
Variable Regression 
Coefficient
Standard 
Error
Adjusted 
Odds 
Ratio
Lower 
95% 
Limit
Upper 
95% 
Limit
P - 
Value
Age 0.01 3.43 1.01 0.97 1.04 0.68
Duration of 
diabetes 
>=10 years
1.23 0.26 3.44 2.06 5.74 <0.00
1
Insulin de-
pendency
1.08 0.27 2.96 1.75 5.00 <0.00
1
Log Blood 
Glucose
1.32 0.40 3.73 1.69 8.22 0.001
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Firstly, the variables have to be combined into different categories to identify the best group-
ing to detect a case i.e. presenting with treatment-requiring diabetic retinopathy. A challenge 
is to redefine the cut-off for the blood glucose level to aid with the grouping and to fit with 
the two other binary variables. 
Three algorithms are presented in Table 9, with their performance in terms of sensitivity (abil-
ity to pick up cases needing to be prioritised), specificity (the ability to exclude those without 
disease), and positive and negative predictive values. 
The first algorithm makes use of insulin dependency and duration of diabetes equal to or 
more than ten years, and excludes blood glucose level as a parameter. 
The second algorithm combines insulin dependency, duration of diabetes of more than ten 
years and blood glucose level greater than 8 mmol.L. The therapeutic goal of anti-diabetic 
treatment for blood glucose level is aimed at a fasting blood glucose level of 8 mmol.L. 
The third algorithm combines the duration of diabetes of more than five years, insulin depen-
dency and blood-glucose level average of equal or more than 8 mmol.L. 
Table 9: The measures of validity for the different algorithms
Algorithm 
Versions
Sensitivity (%) Specificity (%) Positive 
predictive 
value (%)
Negative 
predictive 
value (%)
Version 1 50.5 (95% CI: 
40.8 - 60.2)
85.0 (95% CI: 
81.0 - 89.0)
53.1 83.6
Version 2 48.5 (95% CI: 
38.8 - 58.2)
88.9 (95% CI: 
85.4 - 92.4)
59.5 83.7
Version 3 61.2 (95% CI: 
51.9 – 70.5)
76.8 (95% CI: 
72.1 - 81.5)
47.0 85.5
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The highest sensitivity achieved with the different permutations were with the third algo-
rithmic version. Figure 5 below clearly indicate that the specific combination of variables 
used for the third algorithm show that 65% of all cases fall into that category. 
 
 
Figure 5: Statistical significant variable groupings with proportion of cases and controls per group-
ing. 
This indicates that incorporating the third algorithm as a pre-screening tool we shall correctly 
identify two-thirds of the cases. More than 20% of the controls also fall into that category, which 
means that there shall be false positives identified as well. 
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CHAPTER FIVE: DISCUSSION 
There have been numerous large scale studies quantifying risk factors for diabetes and sub-
sequent onset of complications (Mash and Levitt, 2003). However, there is little research on 
the relationship between biomarkers and diabetes onset and subsequent diabetic complica-
tions within the South African context. Moreover, studies have tended to group the wide va-
riety of diabetes complications together and examined associations for all simultaneously 
(Mash, 2010). 
A hierarchical approach to research on diabetic complications seems to exist with macro- 
vascular complications such as myocardial infarction receiving more attention (in research) 
than micro-vascular complications such as diabetic retinopathy. This could be due to the 
focus on life-saving interventions, combined with the historical difficulty of measuring di-
abetic ocular complications and the presumption of inevitable ocular complications regard-
less of risk factor control (Mollentze, 2003). 
This study sought to establish risk factors associated specifically with treatment-requiring 
diabetic retinopathy based on fundal imagery. The study included 453 participants, of whom 
113 (24.9%) were cases and 340 (75.1%) were controls. The majority of the study partici-
pants were over the age of 50 years. This age profile is similar to that found in the South 
African National Health and Nutrition Examination Survey (SANHANES-1) (NDOH, 2012), 
which found that the rate of diabetes increased almost five fold from 45 to 65 years of age for 
both male and females. The study participants included three times more females than males. 
The SANHANES-1 (NDOH, 2012) also found that females constitute the majority of the 
Western Cape diabetic population, although this ratio was less pronounced than that of the 
study participation (1.3:1). This suggests that there was an over-sampling of females which 
might indicate the poor attendance of the DRS programme by males. The mean body mass 
index in both cases and controls was greater than 30, indicating high level of obesity amongst 
the study participants. However, obesity is also high in the general population. Western 
Cape’s female population has shown to have a prevalence of obesity (BMI > 30) of 37.9% 
(NDOH, 2012). 
Just under a third of cases and controls were recorded as being smokers, similar to 
background levels for the Western Cape (NDOH, 2012). 
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The risk factors investigated were those identified through literature review indicated to be 
associated with the onset of diabetes and the associated complications, and are routinely (in 
most instances) measured at clinic level and readily available to the health work force. 
Three factors were significantly associated with treatment-requiring diabetic retinopathy 
on multivariate analysis: Insulin dependency (OR of 2.96, 95% CI: 1.75 – 5.00); dura-
tion of diabetes of more than 10 years (OR of 3.44, 95% CI: 2.06 – 5.74) and sustained 
hyperglycaemia over the past six months (OR of 3.73, 95% CI:1.69 – 8.22). 
Cases were significantly older than controls on linear regression. However, on multivariate 
analysis this association disappeared. The Early Treatment of Diabetic Retinopathy Study 
(ETDRS) found age to be a significant factor in the progression of diabetic retinopathy. The 
age of onset of diabetes was shown to be more important than the actual age of the patient, 
which is more an indication of the duration of diabetes (Mehlsen et al., 2011). 
Gender of the study participants had no influence on the presentation of treatment-requiring 
diabetic retinopathy. This is in contrast to Mehlsen et al. (2011) who found a higher propor-
tion of treatment-requiring diabetic retinopathy amongst men than women, and the United 
Kingdom Prospective Diabetic Study (UKPDS) where the incidence of diabetic retinopathy 
was higher in men than women. Given the relatively low ratio of men to women in the study 
population of the current study, one possible explanation is that those men most at risk are 
not attending health services. 
This research found that type II diabetics on anti-diabetic treatment for more than ten years 
have a higher likelihood to present with treatment-requiring diabetic retinopathy than those 
on treatment for less than ten years. This has been found in other studies (Ciulla et al., 2003). 
The exact mechanism of how diabetes effects changes to the retina is not clear, however it is 
commonly taken that these changes do occur over a period of time and that the changes fol-
low a natural progression. Mehlsen et al. (2011) found in their research to optimize the DRS 
interval that type II diabetics reached a treatment end-point in a shorter time frame than type 
I diabetics.This might be explained by the delayed diagnosis of type II diabetes. 
Insulin dependency was statistically associated with the presentation of treatment-requiring 
diabetic retinopathy. Aspelund et al. (2011) as well as the ETDRS also found the usage of 
insulin in type II diabetics as a risk factor for diabetic-related complications.  
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Whether the association is due to the usage of insulin as treatment or an indication of poor 
blood-glucose control is not well established. 
The American Diabetes Association (1998) has pointed out that the association of hypergly-
caemia and diabetic-related complications was well established in the early part of the twen-
tieth century. However, only recently has that association been investigated through obser-
vational/experimental studies on both animal and humans alike, and the strength of associa-
tion quantified. The more accurate indication of hyperglycaemia is given by the individual’s 
HbA1c level. However, due to the significant number of individuals’ HbA1c level missing 
on data collection, this could not be considered in the multivariate analysis. 
Mehlsen et al. (2011) found that elevated HbA1c is significantly associated with diabetic 
retinopathy requiring treatment. The United Kingdom Prospective Diabetes Study (UKPDS) 
the largest study concerned with the relationship between glycaemic control and diabetic- 
related complications in Type II diabetics found that the extent of the glycaemic control is 
also important, i.e. the level of reduction in HbA1c reading: for every percentage of HbA1c 
lowered there is 35% reduction in risk of microvascular complications and a 25% reduction 
in diabetes-related death (American Diabetes Association, 1998). 
The UKPDS did not propose a glycaemic threshold, suggesting that continued intensive 
glycaemic control which lowers the HbA1c level brings an equal reduction in microvascular 
complications (American Diabetes Association, 1998). 
The role of better diabetic control (i.e. lowering of the blood-glucose level) in slowing the 
progression or preventing the onset of diabetic-related complications is not fully understood 
and to some extent controversial. The Diabetes Control and Complications Trial (DCCT) a 
prospective study restricted to Type I diabetics, showed a statistically significant risk reduc-
tion in the onset and progression of microvascular complications with the reduction in blood 
glucose level over time. However, there were no statistically significant reductions in car-
diovascular complications (DCCT, 1993). The University Group Diabetes Program (UGDP) 
in 1970 first showed that the lowering of blood-glucose levels with oral antidiabetic drugs 
(Sulfonylureas) may in fact lead to an increase in cardiovascular events. Unlike the UGPD 
study, the UKPDS did not find increased levels of cardiovascular events with use of oral an-
tidiabetic drugs. 
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Mash (2010) indicated that certain lifestyle factors e.g. smoking, alcohol consumption and 
psychological stress, may have an impact on diabetic control and complications. 
A recent systematic review has indicated that the onset of type II diabetes is higher amongst 
smokers, although paradoxically cessation of smoking also tends to increase the risk of type 
II diabetes relative to those who have never smoked (Sattar, Sorensen, Taylor, Morris and 
Munafo, 2015). This research found the same levels of smoking prevalence in cases and 
controls. The Body Mass Index (BMI) of the study participants was not associated with the 
presentation of treatment-requiring diabetic retinopathy. 
Type II diabetes tends to occur concurrently with other metabolic conditions such as hy-
pertension and dyslipidaemia. Ciulla et al. (2003) in their review, indicated that many 
studies have demonstrated the role of these metabolic conditions combined with elevated 
blood-glucose levels in the pathophysiology of diabetic retinal changes. 
The study participants had a high prevalence of hypertension (89.2%) and a moderate preva-
lence of dyslipidaemia (22.5%). However, unlike the research conducted by Ciulla et al. 
(2003) these associated metabolic disorders had no relationship with the presence of treat-
ment-requiring diabetic retinopathy. The high proportion of hypertensive co-morbidity may 
have influenced the grade of retinopathy of fundal images, as hypertension also lead to retinal 
vasculature changes which may mimic diabetic retinopathy changes and should be included 
as a limitation. This was the scenario in the Hoorn Study (van Leiden et al., 2003) where hy-
pertension was found to be associated with the onset of diabetic retinopathy, and was consid-
ered a confounder. Mehlsen et al. (2011) found that although diastolic blood pressure was 
associated with the presentation of treatment-requiring diabetic retinopathy, this was not sta-
tistically significant. An additional limitation to this study was the omission of the clinical 
measurement of hypertension per participant. The folder review was merely concerned with 
the presence of anti-hypertensive treatment and not the clinical measurement thereof. The 
clinical measurement of hypertension might have had an impact on the overall algorithm due 
to the close relationship between hypertensive and diabetic control. 
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The study also sought to develop an algorithm for prioritising those most at risk of develop-
ing treatment requiring diabetic retinopathy. The most important parameter would be sensi-
tivity, as the follow up fundal photography of those prioritised would be to establish if those 
identified as being at risk of diabetic retinopathy actually do have the condition. The highest 
sensitivity with the use of the algorithm was obtained by combining patients on anti- diabetic 
treatment for more than five years, insulin dependent and blood-glucose level of more than 8 
mmol.L. The sensitivity level (61.2%) would still miss four out of ten patients presenting 
with treatment-requiring diabetic retinopathy and is thus not recommended at this stage as an 
effective pre-screening tool. Mehlsen et al. (2011) postulates that the algorithm should make 
use of only a select bunch of clinical markers to lessen the complexity and increase the up-
take thereof. Further investigation will be needed to evaluate this process and further identify 
factors that would define a sub-group with extreme accuracy. 
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CONCLUSION AND RECOMMENDATIONS 
The findings indicate that a sub-set of patients attending the DRS programme in the Klip-
fontein and Mitchells Plain Sub-Districts have a greater likelihood of presenting with treat-
ment-requiring diabetic retinopathy. However, the sensitivity of an algorithm incorporating 
these risk factors as a pre-screening tool amongst the study participants is not sufficient for it 
to be recommended as a screening tool. 
The surge in diabetes with the subsequent increase incidence of diabetic retinopathy (espe-
cially in the working-age population) will add pressure to the current eye care services ren-
dered in Cape Town. Current diabetic eye care guidelines insist on annual fundal imagery, 
especially in resource-scarce countries where secondary prevention is stressed and should not 
be compromised. However, presently we are still struggling to clear the backlog of diabetics 
who have never undergone a fundal examination, compounded by increases in newly diag-
nosed diabetics. This necessitates further evaluation of how to use the existing resources as 
effectively as possible. 
Further investigation of the accuracy of the algorithm can be conducted at clinical level, and 
from there alterations to the algorithm may be made to increase the sensitivity of clinical 
markers. Using the approach developed by Aspelund et al. (2011) research could also inves-
tigate the possibility of extending the DRS interval based on the individual risk factors of 
the diabetic. 
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APPENDICES 
INFORMATION SHEET 
Project Title: Factors associated with diabetic retinopathy requiring 
treatment on fundal photography in participants of the Cape Town 
Diabetic Retinopathy Screening programme. 
What is this study about? 
This is a research project being conducted by Mr HG Alexander at the University of the 
Western Cape. We are inviting you to participate in this research project because you are dia-
betic patient receiving medical care at a community health centre within the circumscribed 
study area. The purpose of this research project is to ascertain if there is any notable differ-
ences amongst the characteristic of a diabetic patient who presents with treatment-requiring 
diabetic retinopathy and those who present with non-treatment-requiring diabetic retinopathy. 
What will I be asked to do if I agree to participate? 
You will be asked to undergo retinal camera imaging which will coincide with your diabetic 
visit at your attending clinic. Thereafter an interviewer will ask you some general information 
with regards to your overall health and well-being. The other relevant study information will 
be sourced from your clinical folder. 
Would my participation in this study be kept confidential? 
We will do our best to keep your personal information confidential. To help protect your 
confidentiality, a code will be assigned to each patient thus keeping your particulars con-
fidential. The review of the folders will be conducted on-site with permission from the 
relevant facility manager. 
What are the risks of this research? 
There are no risks associated with participating in this research project beyond the usual care 
you receive at the clinic. 
What are the benefits of this research? 
The benefits to you is to have the back of your eye photographed and evaluated by a pro-
fessional grader, and include the necessary follow up care. The study forms part of the 
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current diabetic retinal screening program conducted at your facility, and the information 
obtained will lead to future improvements. 
Do I have to be in this research and may I stop participating at any time? 
Your participation in this research is completely voluntary. You may choose not to take part at 
all. If you decide to participate in this research, you may stop participating at any time. If you 
decide not to participate in this study or if you stop participating at any time, you will not be 
penalized or lose any benefits to which you otherwise qualify 
Is any assistance available if I am negatively affected by participating in this study? 
If you feel that partaking in the study had a negative impact either socially, emotionally 
and/or physically then assistance will be provided from the relevant facility managers. 
What if I have questions? 
This research is being conducted by, Mr HG Alexander from the University of the Western 
Cape.  If you have any questions about the research study itself, please contact myself at: 
The Woodstock Hospital (Eye Clinic) 
Mountain Road 
Woodstock 
7925 
Tel: (021) 447 0007 
Email: henry.george.alexander@gmail.com 
Should you have any questions regarding this study and your rights as a research participant 
or if you wish to report any problems you have experienced related to the study, please con-
tact: 
Director: 
Prof Helene Schneider 
School of Public Health 
University of the Western Cape 
Private Bag X17 
Bellville 7535 
hschneider@uwc.ac.za 
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Dean of the Faculty of Community and Health Sciences: 
Prof Jose Frantz 
University of the Western Cape 
Private Bag X17 
Bellville 7535 
chs-deansoffice@uwc.ac.za 
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OFFICE OF THE DEAN
DEPARTMENT OF RESEARCH DEVELOPMENT
08 June 2015 
To Whom It May Concern 
I hereby certify that the Senate Research Committee of the University of the 
Western Cape approved the methodology and ethics of the following research 
project by: 
Mr HG Alexander (School of Public Health) 
Any amendments, extension or other modifications to the protocol must be 
submitted to the Ethics Committee for approval. 
The Committee must be informed of any serious adverse event and/or 
termination of the study. 
 
Ms Patricia Josias 
Research Ethics Committee Officer 
University of the Western Cape 
Research Project: Factors associated with diabetic retinopathy re-
quiring treatment based on fundal photography 
in participants of the Cape Town Retinal Screen-
ing Programme.
Registration no: 15/4/35
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!  
Place Clinic Sticker here 
 
DA PAT
FIRST NAME SURNAME GENDER
ID AGE CHC
TEL NO ADDRESS
OCULAR HISTORY
DIABETES 
TYPE OF TREATMENT
DIAB
ETE
S CO-MORBIDITIES ORAL SUPPLEMENTS
SMOKING NO  YES ….NUMBER OF PACKS PER DAY
ALCOHOL CONSUMPTION …… DRINKS PER WEEK
DATE OF LAST FUNDUS PHOTOGRAPH DRS ATTENDANCE HISTORY IN THE PAST FIVE YEARS
CLINICAL MEASUREMENT CLINICIAN:
HEIGHT WIEGHT BP WASIT CIRCUMFERENCE
BLOOD GLUCOSE 
LEVEL
TODAY 6 MONTH AVERAGE ONE YEAR AGO
MOST RECENT HBA1C PEDAL EXAM
EYE EXAMINATION CLINICIAN:
HABITUAL VISUAL ACUITY R L
PINHOLE VISUAL ACUITY R L
INTRA OCULAR PRESSURE R L
RED REFLEX PRESENT R L
PUPIL REFLEX R L
DIABETIC RETINOPATHY SCREEN-
ING 
CLINICIAN:
RIGH
T 
EYE 
GRA
LEFT 
EYE 
GRAD
ING
FOLLOW UP 
CARE
NO DIABETIC RETINOPATHY ANNUAL REVIEW
MILD/ MODERATE DIABETIC RETINOPATHY 6 MONTHS REVIEW
SEVERE DIABETIC RETINOPATHY REFER TO OPTOMETRIST
PROLIFERATIVE DIABETIC RETINOPAHTY REFER FOR TREATMENT
MACULAR INVOLVEMENT
I ………………………. HEREBY DECLARE THAT THE NATURE OF THE STUDY WAS CLEARLY EXPLAINED 
TO ME, AND THAT I CONSENT TO PARTAKING IN THIS STUDY.
 
 
 
 
